Suggestions
Liz Barrett
CEO at UroGen Pharma
Liz Barrett is the President and Chief Executive Officer of UroGen Pharma, a biopharmaceutical company specializing in therapies for urological-oncology diseases. She has an extensive background in the pharmaceutical industry, particularly in oncology, with over 30 years of experience in various leadership roles.
Career Highlights
-
UroGen Pharma: Barrett joined UroGen in January 2019, where she has been instrumental in guiding the company through its early development stages and overseeing its transition to a commercial-stage entity. Under her leadership, UroGen has focused on innovative treatments for urothelial cancers, utilizing proprietary technologies such as reverse-thermal hydrogel for localized drug delivery.123
-
Novartis Oncology: Before joining UroGen, Barrett served as CEO of Novartis Oncology for less than a year, managing a global team of over 10,000 employees across 85 countries.24
-
Pfizer Inc.: She held multiple senior positions at Pfizer, including Global President of Oncology and President of the Specialty Care business unit for North America. Her tenure at Pfizer was marked by significant contributions to the company's oncology portfolio.24
-
Previous Roles: Barrett also worked at Cephalon as Vice President and General Manager of the Oncology business unit and held various roles at Johnson & Johnson, contributing to her robust expertise in pharmaceutical marketing and management.24
Education
Barrett earned a Bachelor of Science degree from the University of Louisiana at Lafayette and an MBA from Saint Joseph's University, focusing on marketing.24
Leadership Philosophy
Barrett is recognized for her visionary leadership and commitment to innovation in oncology. She emphasizes the importance of addressing unmet medical needs and has expressed a strong dedication to improving patient outcomes through advanced therapeutic solutions.35
Overall, Liz Barrett's extensive experience and strategic vision position her as a significant figure in the biopharmaceutical industry, particularly in the realm of oncology treatments.

